ORGANIC LIGANDS THAT ALTER PARATHYROID CELL FUNCTION

Information

  • Research Project
  • 3496055
  • ApplicationId
    3496055
  • Core Project Number
    R43DK043636
  • Full Project Number
    1R43DK043636-01
  • Serial Number
    43636
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1990 - 34 years ago
  • Project End Date
    6/30/1991 - 33 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1990 - 34 years ago
  • Budget End Date
    6/30/1991 - 33 years ago
  • Fiscal Year
    1990
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/27/1990 - 34 years ago

ORGANIC LIGANDS THAT ALTER PARATHYROID CELL FUNCTION

DESCRIPTION (Adapted from the Applicant's Abstract): Recent studies have provided evidence for the presence of a Ca2+ receptor on the surface of parathyroid cells which enables these cells to detect small changes in the concentration of extracellular Ca2+ and thereby alter parathyroid hormone secretion. This Ca2+ receptor is coupled to the mobilization of intracellular Ca2+ and shows many of the biochemical features common to more conventional Ca2+ mobilizing receptors. The only agents known to act at the Ca2+ receptor are di- and trivalent metal cations. The proposed studies examine the possibility that certain organic compounds might behave similarly to extracellular Ca2+ and regulate PTH secretion by acting as ligands at the Ca2+ receptor. Organic polycations (most notably spermine) will be examined for their ability using bovine and human parathyroid cells to: 1) mobilize intracellular Ca2+; 2) increase inositol phosphate formation; 3) decrease cyclic AMP formation; and 4) inhibit PTH secretion. Comparisons of these results will be made with those obtained with extracellular Ca2+ to determine if both organic and inorganic agents react through the same receptor-dependent mechanism. Organic compounds acting similarly to extracellular Ca2+ might then provide lead structures for the development of novel therapeutic agents effective in the treatment of various bone and mineral-related disorders such as hyperparathyroidism and osteoporosis.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    GMB
  • Study Section Name
    General Medicine B Study Section
  • Organization Name
    NPS PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BEDMINSTER
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07921
  • Organization District
    UNITED STATES